The Barbara Ann Karmanos Cancer Institute has launched a new company to build and market a breast cancer screening device invented at the institute, one that uses ultrasound and computer algorithms to assess patients.
The Barbara Ann Karmanos Cancer Institute has launched a new company to build and market a breast cancer screening device invented at the institute, one that uses ultrasound and computer algorithms to assess patients. The spin-off company, called Delphinus Medical Technologies, is dedicated to developing SoftVue as a commercial product. Clinical research has been conducted under an investigational device exemption from the FDA. The company is currently pursuing FDA approval to sell products based on the technology in the U.S. More than 300 women have been studied in initial clinical trials, which the company says has confirmed SoftVue as safe and accurate in identifying breast cancer.
Study: Mammography AI Leads to 29 Percent Increase in Breast Cancer Detection
February 5th 2025Use of the mammography AI software had a nearly equivalent false positive rate as unassisted radiologist interpretation and resulted in a 44 percent reduction in screen reading workload, according to findings from a randomized controlled trial involving over 105,000 women.